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Abstract: In an effort to probe the structure and function of a predicted
mitochondrial glyoxalase 2, GLX2−1, from Arabidopsis thaliana, GLX2−1 was
cloned, overexpressed, purified and characterized using metal analyses,
kinetics, and UV–visible, EPR, and 1H-NMR spectroscopies. The purified
enzyme was purple and contained substoichiometric amounts of iron and
zinc; however, metal-binding studies reveal that GLX2−1 can bind nearly two
equivalents of either iron or zinc and that the most stable analogue of
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GLX2−1 is the iron-containing form. UV–visible spectra of the purified enzyme
suggest the presence of Fe(II) in the protein, but the Fe(II) can be oxidized
over time or by the addition of metal ions to the protein. EPR spectra revealed
the presence of an anti-ferromagnetically-coupled Fe(III)Fe(II) centre and the
presence of a protein-bound high-spin Fe(III) centre, perhaps as part of a
FeZn centre. No paramagnetically shifted peaks were observed in 1H-NMR
spectra of the GLX2−1 analogues, suggesting low amounts of the
paramagnetic, anti-ferromagnetically coupled centre. Steady-state kinetic
studies with several thiolester substrates indicate that GLX2−1 is not a GLX2.
In contrast with all of the other GLX2 proteins characterized, GLX2−1
contains an arginine in place of one of the metal-binding histidine residues at
position 246. In order to evaluate further whether Arg246 binds metal, the
R246L mutant was prepared. The metal binding results are very similar to
those of native GLX2−1, suggesting that a different amino acid is recruited as
a metal-binding ligand. These results demonstrate that Arabidopsis GLX2−1 is
a novel member of the metallo-β-lactamase superfamily.
Keywords: EPR, glyoxalase 2 (GLX2), iron, metallo-β-lactamase fold, zinc

Introduction
The GLX system consists of two enzymes, lactoylglutathione
lyase (glyoxalase I, GLX1) and hydroxyacylglutathione hydrolase
(glyoxalase II, GLX2), that act co-ordinately to convert a variety of αketo aldehydes into hydroxyacids in the presence of glutathione [1].
Thiohemiacetals, which are formed from the spontaneous reaction of
α-oxo aldehydes with glutathione, are converted into S-(2hydroxyacyl)glutathione derivatives by GLX1. GLX2 hydrolyses S-(2hydroxyacyl)glutathione derivatives to regenerate glutathione and
produce hydroxyacids. GLXI can utilize a number of α-oxo aldehydes;
however, the primary physiological substrate of the system is thought
to be MG (methylglyoxal), a cytotoxic and mutagenic compound that is
formed primarily as a byproduct of carbohydrate and lipid metabolism,
and from triose phosphates [2–4].
The GLX system appears to play a critical role in cellular
detoxification processes and has received considerable attention as a
possible antitumour and antimalarial target in animal systems [5–12].
Increased levels of GLX1 and GLX2 mRNA and protein have been
detected in tumour cells, including breast carcinoma cells, while
inhibitors of GLXI and II have been shown to inhibit the growth of
tumour cells in vitro [4,5,8,12–19]. Plasmodium falciparum and the
protozoan Leishmania donovani exhibit high rates of methylglyoxal
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formation and increased levels of GLX1 activity [20]. Alterations in
GLX activity have also been associated with several disease states.
GLX1 and 2 can inhibit the formation of hyperglycaemia-induced
advanced glycation end products, suggesting that these enzymes may
have a role in diabetic microangiopathy [21]. GLX enzymes may also
play a role in the pathogenesis of Alzheimer's disease [22,23]. Finally,
GLX2 has been identified as a target of p63 and p73, and suggested to
be a pro-survival factor of the p53 family of transcription factors [24].
GLX1, which occurs as a single isoenzyme, has been studied
extensively in a number of systems using biochemical computational
and X-ray crystallographic approaches [25]. In contrast, GLX2 exists
as multiple isoenzymes and has been considerably less well
characterized. In humans, a single gene encodes for mitochondrial and
cytoplasmic forms of GLX2 [26]. In contrast, plants contain distinct
genes encoding cytosolic and multiple mitochondrially localized forms
of GLX2 [27]. Five putative GLX2 genes were identified in the
Arabidopsis thaliana genome, including three (GLX2−1, GLX2−4 and
GLX2−5) that were predicted to be localized in the mitochondrion
[27]. The presence of multiple forms of GLX2 in mitochondria is
surprising, because GLX1 and SLG (S-D-lactoylglutathione) have been
observed only in the cytosol [1,13].
GLX2 enzymes belong to the metallo-β-lactamase fold
superfamily of proteins [28,29]. Metallo-β-lactamases typically bind
1−2 equivalents of Zn(II) [30], whereas the rubredoxin:oxygen
oxidoreductase [31] and ZiPD (zinc phosphodiesterase) [32] families
contain di-Fe and di-Zn centres, respectively. One version of
Arabidopsis GLX2 (GLX2−2) was shown to bind zinc, iron and
manganese [28,33,34], whereas GLX2−5 predominantly contains a
Fe(III)Zn(II) centre [35]. Crystal structures of human cytoplasmic and
plant mitochondrial GLX2 showed that the metal-binding and active
site of GLX2 is most similar to that of metallo-β-lactamases L1 from
Stenotrophomonas maltophilia [35–37]. One of the metal-binding sites
(Zn1 site) consists of three conserved histidine residues, a bridging
aspartic acid, and a bridging water/hydroxide. The second metalbinding site (Zn2 site) has two histidines, one bridging Asp, a nonbridging Asp, a terminally bound water and a bridging hydroxide/water
(Figure 1).
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Figure 1
Structure of mitochondrial GLX2−5

GLX2−1, GLX2−4, and GLX2−5 share ∼80 % amino acid
sequence identity and ∼88 % amino acid sequence similarity [27];
however, GLX2−1 exhibits several important differences relative to the
other predicted mitochondrial GLX2 isoenzymes that led us to predict
that it may in fact not be a GLX2 isoenzyme. GLX2−1 is unique among
GLX2 enzymes in that it has an arginine instead of a histidine residue
at position 246 of the conserved metal-binding motif (Figure 2)
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[35,36]. In addition, five out of eight amino acids present at the active
site of human GLX2 (Lys217, Tyr219, Tyr248, Arg325 and Lys328), which are
involved with substrate binding and conserved in GLX2−2, GLX2−4
and GLX2−5 [38,39], are not conserved in GLX2−1. These
observations suggested that GLX2−1 may not contain a dinuclear
metal centre and may not bind glutathione derivatives as substrates.
We therefore overexpressed and purified GLX2−1 and characterized
the protein using metal analyses and UV–visible, EPR, 1H NMR and
EXAFS spectroscopies to understand how the amino acid differences
affect metal binding, substrate specificity, and the structure of the
enzyme. Our results show that GLX2−1 does in fact contain a
dinuclear metal centre; however, it does not utlilize SLG or other GLX2
substrates, and is therefore not a GLX2 enzyme.

Figure 2: Alignment of predicted plant GLXII proteins
The metallo-β-lactamase fold motif is shaded in grey, and substrate-binding ligands
are indicated by triangles. Metal-binding ligands are indicated by #, * indicates the βlactamase fold motif.
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Experimental
Overexpression and purification of Arabidopsis GLX2−1
PCR was conducted on A. thaliana cDNA, with the primers
CCTCCATGGTAAAAATCGAACTGGTGC and
GAGTCGACTCGAGCTCTAGATCTTTTTTTTTT, which generated NcoI and
XhoI sites at the 5′ and 3′ ends of the fragment. The mature Nterminus of the overexpressed GLX2−1 enzyme was chosen to be
identical to that for A.thaliana GLX2−5 [35]. The GLX2−1 PCR
fragment was cloned into pT7−7 using the NcoI and XhoI restriction
sites, and the sequence of the resulting pGLX2−1/pT7−7 plasmid was
confirmed by DNA sequencing. Plasmid pGLX2−1/pT7−7 was
transformed into Escherichia coli BL21(DE3) cells and small-scale
growth cultures were used to maximize the recovery of soluble protein
at different temperatures (15 °C, 25 °C, 30 °C and 37 °C).
The co-expression plasmid, pGroESL, was transformed into
BL21(DE3) E. coli cells containing pGLX2−1/pT7−7 to assist in proper
protein folding. The large-scale overexpression of GLX2−1 was
performed as follows. A 10 ml overnight culture of BL21(DE3) E. coli
containing pGroESL and pGLX2−1/pT7−7 was used to inoculate 1 litre
of LB (Luria–Bertani) medium containing ampicillin (150 μg/ml) and
chloramphenicol (l50 μg/ml) in the presence or absence of 250 μM
Fe(NH4)2(SO4)2 and 250 μM Zn(SO4)2. The cells were allowed to grow
at 37 °C with shaking until they reached an attenuance at 600 nm of
0.6−0.8. Protein production was induced by making the cultures 0.3
mM in IPTG (isopropyl β-d-thiogalactoside), and the cells were shaken
at 15 °C for 24 h. The cells were collected by centrifugation (15 min at
7000 g) and the cell pellets were stored at −80 °C until further use.
The cell pellet was resuspended in 10 ml of 10 mM Mops, pH
7.2, containing 0.1 mM phenylmethylsulfonyl fluoride. The cells were
lysed by 3 passages through a French press at 16 000 lbf/in2 (1 lbf/in2
≈ 6.9 kPa) and the cell debris was removed by centrifugation at 15
000 g for 30 min. The cleared supernatant was dialysed against 2
litres of 10 mM Mops, pH 7.2, overnight at 4 °C and centrifuged for 20
min at 15 000 g to remove insoluble matter. The cleared supernatant
was purified using FPLC with a Q-Sepharose column (1.5 × 12 cm with
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a 25 ml bed volume) that was equilibrated with 10 mM Mops, pH 7.2.
Bound proteins were eluted with a 0−500 mM NaCl gradient in 10 mM
Mops, pH 7.2, at 2 ml/min. Protein purity was ascertained by
SDS/PAGE. Fractions (8 ml) containing GLX2−1 were pooled and
concentrated by an Amicon ultrafiltration cell equipped with a YM-10
membrane. Enzyme concentrations were determined by measuring the
absorbance at 280 nm and using a molar absorption coefficient of 25
400 M−1 · cm−1, which was determined by using a Bio-Rad protein
assay and BSA as the standard.

Metal analyses
The metal content of GLX2−1 samples was determined using a
Varian-Liberty 150 ICP-AES (inductively-coupled plasma spectrometer
with atomic emission spectroscopy detection) as described previously
[28]. Protein samples were diluted to 10 μM with 10 mM Mops, pH 7.2.
A calibration curve with four standards and a correlation coefficient of
greater than 0.99 was generated using Fe, Zn and Mn reference
solutions. The following emission wavelengths were chosen to ensure
the lowest detection limits possible: Fe, 259.940 nm; Zn, 213.856 nm;
and Mn, 257.610 nm.
To evaluate metal binding to GLX2−1, a 5-fold molar excess of
Fe(NH4)2(SO4)2, Zn(SO4)2 or Fe(NH4)2(SO4)2 plus Zn(SO4)2 were added
directly to 10 μM apo-GLX2−1, and the mixtures were allowed to
incubate on ice for 1 h. Unbound metal ions were removed by four 1
litre dialysis steps against 10 mM Mops, pH 7.2, at 4 °C (12 h for each
dialysis step). The metal content of these protein samples was
determined using ICP-AES as described above.

Spectroscopic studies
UV–visible spectra were recorded using an Agilent 8453 UVvisible spectrophotometer at 25 °C. GLX2−1 concentrations were
approx. 1.0 mM, and the buffer was 10 mM Mops, pH 7.2. Difference
spectra were generated using Igor Pro version 4.0.5.1 (Wavemetrics).
EPR spectra were recorded using a Bruker E600 EleXsys
spectrometer equipped with an Oxford Instruments ESR900 helium
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flow cryostat and ITC503 temperature controller, and an ER4116DM
cavity operating at 9.63 GHz in perpendicular mode. Other recording
parameters are given in Figure 3. Quantification of signals was carried
out by double integration of spectra recorded at non-saturating power
(2 mW) at 12 K. A 2 mM Cu(II)-EDTA standard in Hepes buffer, pH
7.5, recording at 60 K, 50 μW, was used. Integration limits and
correction factors for S = ½ and S=52 signals where D is assumed to
be small compared with temperature, were as employed elsewhere
[39a] and described explicitly by Bou-Abdallah and Chasteen [39b]
and references therein [39c]. Computer simulations of EPR spectra
were carried out using XSophe (Bruker Biospin; [39d]).

Figure 3
UV–visible spectrum of 1.2 mM as-isolated GLX2−1 in 10 mM Mops, pH 7.2

H-NMR spectra were collected on a Bruker Avance 500
spectrometer operating at 500.13 MHz, 298 K, magnetic field of 11.7
T, recycle delay of 41 ms, and sweep width of 400 p.p.m. Chemical
shifts were referenced by assigning the H2O signal a value of 4.70
p.p.m. A modified presaturation pulse sequence (zgpr) was used to
suppress the proton signals originating from solvent and amino acids
1
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not coupled to the metal centre. The concentration of protein was
approx. 1 mM, and 10 % 2H2O was included in samples for locking.

Substrate specificity studies
A series of thioesters of glutathione were used for the
preliminary investigation of substrate specificity of as-isolated and
Fe(II)-added GLX2−1. The substrates used were SLG (ε240 = 3100 M−1
· cm−1), S-mandeloylglutathione (ε263 = 4200 M−1 · cm−1), Sacetylglutathione (ε240 = 2980 M−1 · cm−1), S-acetoacetylglutathione
(ε240 = 3400 M−1 · cm−1), S-formylglutathione (ε240 = 3300 M−1 ·
cm−1), S-glycolylglutathione (ε240 = 3260 M−1 · cm−1) and Slactonylglutathione (ε240 = 3310 M−1 · cm−1). With the exception of
SLG, all substrates were synthesized as described elsewhere [40].
Thioester hydrolysis was monitored at 240 nm (except Smandeloylglutathione, 263 nm) over 60 s at 25 °C as previously
reported [15]. The concentrations of as-isolated and Fe(II)-added
enzyme were 10−300 μM, and substrates used were 30−600 μM.

Overexpression and purification of the R246L mutant of
GLX2−1
The QuikChange® site-directed mutagenesis kit was used to
prepare the R246L mutant of GLX2−1. PCR was conducted on plasmid
GLX2−1/pT7−7 with the primers
CAAATATATACTGCGGCCTTGAAAACACAGCAGGC and
GCCTGCTGTGTTTTCAAGGCCGCAGTATATATTTG. The sequence of the
resulting R246L-GLX2−1/pT7−7 plasmid was confirmed by DNA
sequencing using the T7 promoter and T7 terminator primers. Plasmid
R246L-GLX2−1/pT7−7 was transformed into E. coli BL21(DE3) cells.
The R246L mutant was overexpressed as described above, and the
resulting protein was insoluble. The co-expression plasmid, pGroESL,
was transformed into BL21(DE3) E. coli cells containing R246LGLX2−1/pT7−7 to assist in proper protein folding. The R246L mutant
was then overexpressed and purified as described above.
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Results
Overexpression and purification of A. thaliana GLX2−1
Sequence comparisons of different GLX2 isoenzymes indicated
that GLX2−1 has a N-terminal mitochondrial targeting sequence [27].
Therefore, this N-terminal leader was removed during sub-cloning to
generate an N-terminus of MKIELVP (Figure 1), which is similar to that
of recombinant GLX2−5, for overexpression of GLX2−1 in E. coli [35].
GLX2−1 could be overexpressed at high levels in E. coli BL21(DE3)
cells; however, at temperatures > 15 °C, no soluble GLX2−1 was
recovered. When GLX2−1 was overexpressed at 15 °C, some soluble
protein was detected in the cleared lysates; however, the recombinant
GLX2−1 did not bind to Q-Sepharose or SP-Sepharose columns at pH
values ranging from 6 to 8. This result suggested that the
overexpressed GLX2−1 was improperly folded. BL21(DE3) E. coli cells,
containing the pGLX2−1/pT7−7 plasmid, were then transformed with
pGroESL, and the previously mentioned overexpression/purification
protocol was followed in an effort to produce properly folded
recombinant GLX2−1. Overexpression of GLX2−1 in the presence of
pGroESL at 15 °C resulted in high levels of soluble recombinant
protein, which was purified with Q-Sepharose chromatography. The
enzyme, which eluted from the column at 100 mM NaCl in 10 mM
Mops, pH 7.2, was purple in colour; however, the colour faded in 7−10
days at 4 °C. Approx. 50 mg of purified GLX2−1 per litre of culture
was obtained using this method. The resulting enzyme was shown to
bind substoichiometric amounts of Fe and Zn(II), ranging from
0.1−0.5 equivalent for both metals (Table 1). The enzyme did not
exhibit any SLG hydrolase activity.
Table 1: Metal content of GLX2−1 analogues
Fe (eq) Zn(II) (eq)
Wild-type GLX2−1
No added metal

0.3±0.2

0.3±0.1

250 μM Fe plus Zn(II) added in the medium

0.3±0.1

0.3±0.2

3-fold excess of Fe added after purification

1.9±0.1

0.2±0.1

3-fold excess of Zn(II) added after purification

∼0.1

1.6±0.2

3-fold excess of Fe plus Zn(II) added after purification 1.6±0.2

1.6±0.2

GLX2−1 R246L
250 μM Fe plus Zn(II) added in the medium

∼0.1

0.6±0.1
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Fe (eq) Zn(II) (eq)
3-fold excess of Fe added after purification

2.4±0.5

0.5±0.2

3-fold excess of Zn(II) added after purification

0.1

1.4±0.2

Metal content of recombinant GLX2−1
The substoichiometric levels of metal suggested that the
enzyme may still not be folding properly or may need higher relative
metal concentrations for metal binding. Therefore GLX2−1 was
overexpressed in LB medium containing 250 μM Fe(NH4)2(SO4)2 and
250 μM Zn(SO4)2, conditions that had previously been shown to result
in stoichiometric binding of Fe and Zn to GLX2−5 [35]. When GLX2−1
was overexpressed in the presence of 250 μM Fe(II) + 250 μM Zn(II),
the purified protein was found to contain between 0.1−0.5 equivalents
of Fe and between 0.1−0.5 equivalents of Zn(II) (Table 1). Therefore,
the addition of metal ions to the growth medium did not greatly affect
the amount of metal ions bound to purified GLX2−1. This result was
surprising, since similar studies on Arabidopsis GLX2−2 showed that
the amounts and identity of metal ion bound to the purified enzyme
were greatly affected by metal ion present in the growth medium
[33,34].
We further investigated the ability of GLX2−1 to bind metal by
the addition of metal to the as isolated protein. The addition of a 5-fold
molar excess of Fe(NH4)2(SO4)2, Zn(SO4)2 or both metal ions to the
isolated purple protein in the presence or absence of a 10-fold molar
excess of DTT (dithiothreitol) resulted in an immediate change in
colour to brownish-yellow followed by protein precipitation. However,
the slow addition of a 3-fold molar excess of metal ions did not result
in protein precipitation. After exhaustive dialysis, the resulting protein
was shown to bind 1.8−2.1 equivalent of Fe and 0.1−0.2 equivalents
of Zn(II), 0.1 equivalents of Fe and 1.6 equivalents of Zn(II), and 1.6
equivalents of Fe and 1.6 equivalents of Zn(II) after addition of
Fe(NH4)2(SO4)2, Zn(SO4)2, or both metals respectively (Table 1). The
Zn(II)-added protein was unstable and precipitated within 1 h. None of
the metal-loaded forms of GLX2−1 exhibited any SLG hydrolase
activity.
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Spectroscopic studies on GLX2−1
We predicted that the presence of an arginine residue at
position 246 of GLX2−1 would disrupt the GLX2 binuclear metalbinding centre and interfere with the ability of the protein to bind two
metal atoms. However, our observation that GLX2−1 can bind two
equivalents of metal, if excess metal is added to the purified protein,
suggested that either Arg246 acts as a metal-binding ligand, or more
likely another amino acid is recruited as a ligand. Spectroscopic studies
were conducted on GLX2−1 to probe the metal binding site of enzyme.
The UV–visible spectrum of the as-isolated protein showed a broad
peak with maximal absorbance at 540 nm and an absorption
coefficient of 129 M−1 · cm−1 (Figure 3). The intensity of this peak
suggests that it is due to a ligand field (d-d) transition of high-spin
Fe(II) [41]. This assignment is consistent with the observed loss of
colour of the as-isolated GLX2−1 over time and when metal ions are
added to the as-isolated protein, since both of these scenarios would
lead to oxidation of Fe(II) to Fe(III), which would not exhibit any spinallowed electronic transitions [41].
We next attempted to characterize the metal-binding site of
GLX2−1 by using paramagnetic 1H-NMR spectroscopy. Despite
considerable effort, we were unable to obtain an NMR spectrum of the
as-isolated protein, most likely due to very small levels of
paramagnetic centres in the as-isolated protein. We were also
unsuccessful in obtaining a spectrum for the Fe-loaded form of
GLX2−1. This result is consistent with the UV–visible results that
suggest that this protein probably contains only Fe(III). The presence
of mononuclear Fe(III) or diamagnetic Fe(III)Fe(III) would result in no
detectable paramagnetically shifted peaks [42].
We further characterized the as-isolated GLX2−1 using EPR
spectroscopy. The EPR signal from as-isolated GLX2−1 (Figure 4A)
contained contributions from at least two separate chemical species.
The spectrum was dominated by an intense resonance at geff ∼ 4.3 due
to Fe(III). Other transitions that are attributed to Fe(III) were also
observed at 750 G (75 mT; geff ∼ 5.6), 900 G (90 mT; geff ∼ 7.6), 1430
G (143 mT; geff ∼ 4.8), 1730 G (173 mT; geff ∼ 4.0) and 1850 G (185
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mT; geff ∼ 3.7), The 750−2000 G (75−200 mT) region of the spectrum
could not be simulated using a single set of spin Hamiltonian
parameters and the simple E/D-strain model in XSophe. The
unsuccessful attempts at simulation suggested that there are two
distinct species responsible for the multiple transitions between 750 G
and 1850 G with strains in E/D that are relatively moderate compared
to the large strains observed for adventitious Fe(III). The lack of
resolved splitting of the geff = 4.3 line suggests that a third species
may additionally contribute to the intensity at geff = 4.3. These data
indicate the existence of at least one and more likely two sites in
GLX2−1 that bind Fe(III) in a constrained environment, in addition to
possible adventitious binding sites.

Figure 4: EPR spectra of GLX2−1
Trace A is the EPR spectrum of as-isolated GLX2−1. Trace B is a computer simulation
assuming two spin-coupled iron ions in an Fe(III)Fe(II) centre. Trace C is the
spectrum of GLX2−1 after aerobic addition of Fe(II). Trace D is an expanded view of
Trace A and Trace E is of GLX2−1 after aerobic addition of Fe(II). Experimental
conditions were: A, 12 K, 2 mW; C, 10 K, 1 mW; D, 12 K, 2 mW; E, 10 K, 20 mW.
Spectra A and C are shown normalized for temperature and microwave power; spectra
D and E are shown with arbitrary intensities. 10 G (1 mT) magnetic field modulation at
100 kHz was employed and other parameters were chosen such that spectral
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resolution was limited by the field modulation. The parameters used for the simulation
of Trace B were: for Fe(III), S=52, gisotropic = 2.0, D = 2 cm−1 and E/D = 0; for Fe(II),
S = 2, g(x,y,z) = 1.970, 2.090, 2.025, D = 15 cm−1 and E/D = 0.2; for the dinuclear
centre, J = 43 cm−1 and an inter-iron distance, r, of 3.6 Å (0.36 nm) was assumed. It
should be noted that (i) this is not a unique solution, and (ii) the simulation was not
sensitive to all the parameters; in particular, the dependence on r and on which iron
was assumed to have a rhombic zero-field splitting term was slight.

The other feature observed in the EPR spectrum of GLX2−1 was
a signal that exhibited geff values of 1.946, 1.844 and 1.775. In
comparison with mitochondrial GLX2−5, that exhibits this type of
signal [35], the high field signal from GLX2−1 can be attributed to an
Fe(III)Fe(II) dinuclear centre. The Fe(III)Fe(II) centre could be
simulated to very good agreement (Figure 4B) assuming such a spincoupled centre with reasonable spin Hamiltonian parameters
(SFe(III)=52; SFe(II) = 2; gFe(III) = 2.0; gFe(II) > 2.0; DFe(III) = 2 cm−1;
DFe(II) = 15 cm−1; J = 43 cm−1; the solution is not unique and detailed
parameters are given in the legend to Figure 4). The presence of this
feature in the spectrum supports the assignment of the lower field
features to Fe(III) in two distinct iron-binding sites in GLX2−1.
Upon the aerobic addition of Fe(II) to GLX2−1, the purple colour
was lost, and this loss was concomitant with the loss of the
Fe(II)Fe(III) EPR signal (Figure 4C). In addition, subtle changes in the
low-field region of the spectrum were observed (Figures 4C–4E). While
the features at 1430 G (143 mT) and 1730 G (173 mT) were
preserved, the signals at 1430 G (143 mT) and 1850 G (185 mT) were
broadened considerably, and changes in the 700−900 G (70−90 mT)
region were also apparent. It is noteworthy that the loss of the
Fe(III)Fe(II) signal was not accompanied by an increase in the spin
density due to Fe(III). The estimated spin coupling constant for the
Fe(III)Fe(II) centre was much higher than the Zeeman interaction,
and a Fe(III)Fe(III) centre with comparable spin coupling would not be
expected to exhibit an EPR signal.
Quantitation of the EPR signals from as-isolated GLX2−1
indicated that the Fe(III)Fe(II) signal accounted for only 25 % of the
spin density. As suggested by the results of the aerobic addition of
Fe(II), it is likely that the fraction of the Fe(III)Fe(II) species would be
highly dependent on sample history, including exposure to air and
contaminating metal ions, and it is perhaps not too surprising that
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attempts at NMR of protons experiencing paramagnetic interactions
with this centre were unsuccessful.

Efforts to identify substrates of GLX2−1
Most GLX2 enzymes exhibit a substrate preference for SLG;
however, none of the recombinant GLX2−1 variants (Table 1)
exhibited any detectable SLG hydrolase activity. Therefore to probe
whether GLX2−1 is a GLX2 with different substrate specificity, activity
assays with other thioesters of glutathione were conducted in order to
determine if GLX2−1 has GLX activity, but exhibits a preference for
different glutathione thio-esters. Similar to the results with SLG, the
as-isolated purple protein and GLX2−1 containing 2 equivalents of Fe
did not hydrolyse S-mandeloylglutathione, S-acetylglutathione, Sacetoacetylglutathione, S-formylglutathione, S-glycolylglutathione or
S-lactonylglutathione. Therefore GLX2−1 is not a GLX2 enzyme.

Overexpression and purification of the R246L mutant
GLX2−1
Our discovery that GLX2−1 binds two equivalents of metal ions
was unexpected, given that one of the highly conserved GLX2 metalbinding ligands is replaced by an arginine (Arg246) in GLX2−1. Our
observation that GLX2−1 can bind two equivalents of iron or zinc
suggested either that Arg246 has the ability to act as a metal-binding
ligand, or that another amino acid near the active site is recruited as a
metal-binding ligand.
In order to evaluate further whether the amino acid at position
246 binds the metal, the R246L mutant was made. The rationale was
that the replacement of arginine by leucine, which is not a metalbinding ligand, would result in a mutant that binds only 1 equivalent of
metal. When the R246L mutant was overexpressed at 15 °C, no
soluble protein was detected in cleared lysates, suggesting that the
overexpressed R246L mutant was improperly folded. However, high
levels of soluble protein were obtained when the R246L mutant was
expressed in BL21(DE3) E. coli cells, containing pGroESL. When the
mutant was overexpressed in the presence of 250 μM Fe and Zn(II),
the purified protein was shown to bind 0.1 equivalent of Fe and 0.6 ±
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0.1 equivalent of Zn(II) (Table 1). When excess iron was added to the
purified R246L mutant, as described for wild-type GLX2−1, the
resulting protein bound 2.4 ± 0.5 equivalents of Fe and 0.5 ± 0.2
equivalent of Zn(II). The Zn(II)-added analogue of R246L-GLX2−1
bound 0.1 equivalent of Fe and 1.4 ± 0.2 equivalents of Zn(II). These
results are very similar to those of native GLX2−1. None of these
analogues hydrolysed SLG. These results indicate that Arg246 is not
acting as a metal-binding ligand and that a nearby amino acid is being
recruited as part of the metal-binding centre in GLX2−1.

Discussion
The metallo-β-lactamase fold consists of an αβ/βα sandwich
motif, made up of a core unit of two β-sheets surrounded by solventexposed helices [29]. Members of this superfamily contain a conserved
HXHXD motif that has been shown to bind Zn(II), Fe and Mn. There
are several enzymes in the metallo-β-lactamase fold family, for
example metallo-β-lactamases, GLX2, lactonase, ROO
(rubredoxin:oxygen oxidoreductase), arylsulfatase, phosphodiesterase
and tRNA maturase [43]. Most of the metallo-β-lactamase superfamily
members (metallo-β-lactamases, tRNA maturase, phosphodiesterase,
arylsulfatase and lactonase) appear to contain dinuclear Zn(II)
centres. On the other hand, ROO appears to contain a dinuclear iron
centre [44]. Human GLX2 was reported to contain a dinuclear Zn(II)
centre [36]; however, plant mitochondrial GLX2 (GLX2−5) has been
shown to contain a FeZn centre [35], and plant cytoplasmic GLX2 can
exist with a number of possible metal centres, including dinuclear Fe,
FeZn, MnZn and presumably dinuclear Zn(II) [33,34].
Arabidopsis GLX2−1 is highly similar to GLX2−5 and is clearly a
member of the metallo-β-lactamase fold superfamily [29]. However,
GLX2−1 is unique in that it contains an arginine residue at position
246, which is a metal-binding histidine in all other GLX2 enzymes [43].
Since arginine should be positively charged at neutral pH values, we
hypothesized that GLX2−1 would not contain a dinuclear metal centre.
Therefore, it was not surprising that as-isolated recombinant GLX2−1
contained less than 1 equivalent of total metal. This form of the
protein was purple, and, based on UV–visible studies and the molar
absorption coefficient of the peak at 550 nm, we predict that the
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colouration is due to ligand field transitions of Fe(II) bound to the
protein. The Fe(II) can be oxidized to the colourless Fe(III) during
short term storage or by the addition of metal ions. EPR studies were
conducted to characterize further the metal-binding site in the asisolated protein, and the spectrum clearly shows the presence of
protein-bound high-spin Fe(III). In addition, the spectrum showed the
presence of small amounts, up to 25 %, of an anti-ferromagnetically
coupled Fe(III)Fe(II) centre that has previously been observed in
GLX2−2 and GLX2−5 [33–35] and in the purple acid phosphatases
[45,46]. Addition of metal ions to the sample resulted in the loss of
the Fe(III)Fe(II) signal with no concomitant increase in the Fe(III)
signal, which suggests that the purple colouration arises from Fe(II) in
the Fe(III)Fe(II) centre. The lack of paramagnetically shifted 1H
resonances in the NMR spectra strongly indicates that there are low
levels of either Fe(III)Fe(II) or mononuclear Fe(II). The protons
coupled to Fe(III) would probably be broadened too much for
detection. Our finding that as-isolated GLX2−1 appears to contain a
dinuclear Fe(III)Fe(II) centre, but overall binds less than two
equivalents of metal, may be due to the fact that the metal falls out of
the protein during the purification process because Arg246 does not
allow the enzyme to bind tightly to metal. Taken together, these data
suggest that as-isolated GLX2−1 contains small amounts of a
Fe(III)Fe(II) centre and larger amounts of FeZn [Fe(III) or Fe(II)] and
possibly ZnZn centres. It is also possible that there are significant
amounts of mononuclear Fe(II) or a Fe(III)Fe(III) centre in the
protein.
In an attempt to saturate the metal-binding site, we incubated
the purified protein with excess Zn(II) or Fe, and, after dialysis to
remove loosely bound or unbound metal ions, GLX2−1 was found to
bind nearly 2 equivalents of metal. There does not appear to be
significant discrimination in metal binding, and dinuclear Zn(II), Fe and
FeZn centres can apparently be generated if the protein is incubated
with Zn(II), Fe, or Fe and Zn(II). Empirically, the Zn(II)-containing
analogues are not stable and precipitate relatively quickly once they
are prepared, while the Fe-containing analogues are stable for long
periods of time. It is not clear why the Zn(II)-containing forms of the
protein are unstable. Nonetheless, the ability of GLX2−1 to bind 2
equivalents of metal was unexpected, given that the protein has an
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arginine residue at position 246, which is not a common metal-binding
ligand due to its charge.
In order to investigate further whether Arg246 binds metal, the
R246L mutant was generated and characterized. The resulting protein
after being loaded with Fe and/or Zn(II) exhibited metal-binding
properties similar to those of the wild-type enzyme. The ability of the
R246L mutant to bind 2 moles of metal was unexpected because
leucine is not a metal-binding ligand. This result strongly suggests that
the amino acid at position 246 is not involved in metal binding. Since
the dinuclear metal centre is present, this result suggests that another
active site residue is recruited to bind metal in GLX2−1.
The results of steady-state kinetic studies with GLX2−1, using a
number of different thiolester substrates, indicate that GLX2−1 is not a
GLX2 enzyme. The amino acid sequences of GLX2−1 and GLX2−5
exhibit ∼80% identity and ∼88% similarity [27]. However, five of
seven active-site residues involved with substrate binding
(glutathione) in GLX2−2 [39] and human GLX2 [36] are not conserved
in GLX2−1 (Figure 2). It is possible that the different metal-containing
analogues of GLX2−1 that we generated in this study are not the
physiologically relevant form(s) of the enzyme, or that the absence of
GLX2 activity could be due to improperly folded protein. However,
previous work on GLX2−2 has shown that this enzyme can utilize a
number of different metal centres for catalysis [33,34], and this
scenario certainly would offer the organism (Arabidopsis in this case)
with an evolutionary advantage, because toxins could be removed
regardless of the metal content. The most straightforward
interpretation of the steady-state kinetic studies is that GLX2−1 is not
a GLX2. At this time, the function for GLX2−1 is unknown; however,
molecular studies are being conducted in an effort to identify the
physiological role of this protein. In addition, we are attempting to
solve the crystal structure of the protein in the hope that the activesite structure can offer some clue as to the natural substrate [47]. It is
likely that GLX2−1 will represent a novel function for a metallo-βlactamase superfamily member [43].
Our previous sequence comparison study identified five genes
that were predicted to encode for GLX2 isozymes (GLX2−1, 2−2, 2−3,
2−4 and 2−5) in A. thaliana [27]. We have demonstrated that GLX2−2
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and GLX2−5 are in fact GLX2 enzymes [27,28,35] and that they
contain dinuclear metal-binding sites [34,35,48]. We recently showed
that GLX2−3 contains a mononuclear Fe(II) site [50] and is not a
GLX2 [49]. Moreover, this protein is probably a plant analogue of
ethylmalonic encephalopathy protein 1 [51], which is a human protein
potentially involved with β-oxidation of short-chain acyl-CoAs. The
data presented herein demonstrate that GLX2−1 is also not a GLX2,
but it contains a dinuclear metal binding site. To date, there is no
information on the mitochondrial GLX2−4 protein, and studies are in
progress to address whether this protein is a GLX2.
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S-D-lactoylglutathione
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